培美曲塞对比多西他赛在经治非小细胞肺癌患者中的随机III期试验
这项随机III期试验比较了培美曲塞与多西他赛在既往接受过化疗的晚期非小细胞肺癌(NSCLC)患者中的疗效与毒性。共571例患者随机分组,主要终点为总生存期。两组疗效相当,但多西他赛组3/4级中性粒细胞减少、发热性中性粒细胞减少及住院等不良事件显著更多。作者认为培美曲塞应被视为二线NSCLC的标准治疗选择之一。
要点
- 培美曲塞与多西他赛在经治晚期NSCLC中疗效相当,中位生存期分别为8.3个月与7.9个月。
- 多西他赛组3/4级中性粒细胞减少(40.2% vs 5.3%)和发热性中性粒细胞减少(12.7% vs 1.9%)显著高于培美曲塞组。
- 作者认为培美曲塞毒性更少,应被视为二线NSCLC的标准治疗选择之一。
核心结论
- 培美曲塞治疗在晚期NSCLC二线治疗中疗效与多西他赛临床等效,但副作用显著更少,作者认为应被视为标准治疗选择之一。
研究设计与样本
- 随机III期试验,纳入既往接受过一种化疗方案的晚期NSCLC患者,体能状态0-2分,器官功能充足,共571例患者随机分组。
- 培美曲塞组:培美曲塞500 mg/m2静脉第1天,联合维生素B12、叶酸和地塞米松,每21天一次;多西他赛组:多西他赛75 mg/m2静脉第1天,联合地塞米松,每21天一次。
- 主要终点为总生存期。
主要发现
- 总缓解率:培美曲塞组9.1% vs 多西他赛组8.8%(方差分析P = .105)。
- 中位无进展生存期两组均为2.9个月;中位生存期培美曲塞组8.3个月 vs 多西他赛组7.9个月(P = 不显著)。
- 1年生存率两组均为29.7%。
- 多西他赛组对比培美曲塞组:3/4级中性粒细胞减少40.2% vs 5.3%(P < .001);发热性中性粒细胞减少12.7% vs 1.9%(P < .001);中性粒细胞减少合并感染3.3% vs 0.0%(P = .004);因发热性中性粒细胞减少住院13.4% vs 1.5%(P < .001);因其他药物相关不良事件住院10.5% vs 6.4%(P = .092);使用粒细胞集落刺激因子支持19.2% vs 2.6%(P < .001);所有级别脱发37.7% vs 6.4%(P < .001)。
关键数值与推荐
- 作者结论认为培美曲塞应被视为二线NSCLC的标准治疗选择之一(当可用时)。
临床怎么用
- 作者认为在晚期NSCLC二线治疗中,培美曲塞疗效与多西他赛临床等效且副作用显著更少,应被视为标准治疗选择之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. PATIENTS AND METHODS: Eligible patients had a performance status 0 to 2, previous treatment with one prior chemotherapy regimen for advanced NSCLC, and adequate organ function. Patients received pemetrexed 500 mg/m2 intravenously (IV) day 1 with vitamin B12, folic acid, and dexamethasone or docetaxel 75 mg/m2 IV day 1 with dexamethasone every 21 days. The primary end point was overall survival. RESULTS: Five hundred seventy-one patients were randomly assigned. Overall response rates were 9.1% and 8.8% (analysis of variance P = .105) for pemetrexed and docetaxel, respectively. Median progression-free survival was 2.9 months for each arm, and median survival time was 8.3 versus 7.9 months (P = not significant) for pemetrexed and docetaxel, respectively. The 1-year survival rate for each arm was 29.7%. Patients receiving docetaxel were more likely to have grade 3 or 4 neutropenia (40.2% v 5.3%; P < .001), febrile neutropenia (12.7% v 1.9%; P < .001), neutropenia with infections (3.3% v 0.0%; P = .004), hospitalizations for neutropenic fever (13.4% v 1.5%; P < .001), hospitalizations due to other drug related adverse events (10.5% v 6.4%; P = .092), use of granulocyte colony-stimulating factor support (19.2% v 2.6%, P < .001) and all grade alopecia (37.7% v 6.4%; P < .001) compared with patients receiving pemetrexed. CONCLUSION: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-line NSCLC when available.
引用
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol. 2023. PMID: 37196429. doi:10.1200/JCO.22.02546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。